Ikram Z, Dulipsingh L, Prestwood K M
Division of Endocrinology and Metabolism, University of Connecticut Health Center, Farmington 06030-5215, USA.
J Womens Health Gend Based Med. 1999 Sep;8(7):973-8. doi: 10.1089/jwh.1.1999.8.973.
A number of studies suggest that progestogens have beneficial effects on bone in postmenopausal women, particularly in combination with estrogen, although these studies have used derivatives that may have estrogenic and androgenic properties in addition to effects mediated by progesterone receptors. Progesterone itself affects only progesterone and glucocorticoid receptors. However, until the development of micronized progesterone (MP), absorption of progesterone preparations was too low to be clinically useful. MP has similar protective effects on the uterus and fewer effects on the lipid profile than other preparations, but its effects on bone are unknown. We tested the hypothesis that MP would alter bone turnover, as measured by serum and urine biochemical markers, in postmenopausal women. Fourteen women aged 65 or over who were not on estrogen replacement received a 6-week course of daily MP (200 mg). Markers of bone turnover were measured in serum and urine collected at baseline, at 6 weeks on MP, and 6 weeks after termination of MP. We also measured total and high-density lipoprotein (HDL) cholesterol and progesterone levels during the study. Markers of bone resorption were urinary free deoxypyridinoline cross-linked N-telopeptides and C-telopeptides of type I collagen. Markers of bone formation were serum osteocalcin, bone alkaline phosphatase, and type I C-terminal and N-terminal procollagen peptides. Using repeated measures analysis of variance, markers of bone formation and resorption did not change with MP treatment in spite of an increase in progesterone levels in all women. We conclude that 6-week treatment with MP alone does not have an effect on bone turnover in postmenopausal women in spite of high physiological levels. These data suggest that effects on bone demonstrated using other progestogen preparations might be due to androgenic or estrogenic effects or that progesterone may not affect bone in estrogen-deficient women.
多项研究表明,孕激素对绝经后女性的骨骼具有有益作用,尤其是与雌激素联合使用时,尽管这些研究使用的衍生物除了通过孕激素受体介导的作用外,可能还具有雌激素和雄激素特性。孕激素本身仅作用于孕激素和糖皮质激素受体。然而,在微粉化孕酮(MP)研发出来之前,孕酮制剂的吸收率过低,不具有临床实用性。与其他制剂相比,MP对子宫具有类似的保护作用,对脂质谱的影响较小,但其对骨骼的影响尚不清楚。我们检验了这样一个假设:在绝经后女性中,MP会改变骨转换,这可通过血清和尿液生化标志物来衡量。14名65岁及以上未接受雌激素替代治疗的女性接受了为期6周的每日MP(200mg)疗程。在基线、服用MP6周时以及停用MP6周后收集的血清和尿液中测量骨转换标志物。在研究期间,我们还测量了总胆固醇和高密度脂蛋白(HDL)胆固醇以及孕酮水平。骨吸收标志物为尿游离脱氧吡啶啉交联的I型胶原N-端肽和C-端肽。骨形成标志物为血清骨钙素、骨碱性磷酸酶以及I型前胶原C-末端和N-末端肽。尽管所有女性的孕酮水平均升高,但使用重复测量方差分析发现,骨形成和吸收标志物并未因MP治疗而改变。我们得出结论,尽管生理水平较高,但单独使用MP进行6周治疗对绝经后女性的骨转换没有影响。这些数据表明,使用其他孕激素制剂所显示出的对骨骼的影响可能是由于雄激素或雌激素作用,或者孕酮可能不会影响雌激素缺乏的女性的骨骼。